<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Forty patients with high risk <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo>--<z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts, <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts in transformation, or <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo>--were treated with subcutaneous low dose <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi>, 10 mg/m2 twice daily for up to 42 days </plain></SENT>
<SENT sid="1" pm="."><plain>In 38 evaluable patients there were nine (24%) complete and four (11%) partial responses </plain></SENT>
<SENT sid="2" pm="."><plain>Response was associated with symptomatic improvement and resolution of the need for red cell and platelet transfusions </plain></SENT>
<SENT sid="3" pm="."><plain>The median duration of complete response was 9.8 months (range, 2.4-17.9); these patients had a median survival of 15.7 months (range, 6.0-22.7) </plain></SENT>
<SENT sid="4" pm="."><plain>Toxicities were predominantly those associated with <z:hpo ids='HP_0001876'>pancytopenia</z:hpo>, i.e., <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> and <z:mp ids='MP_0001914'>hemorrhage</z:mp> </plain></SENT>
</text></document>